Pharmaceutical Technology8 小时
Omalizumab biosimilar by Mabpharm for Chronic Urticaria Or Hives: Likelihood of Approval
Omalizumab biosimilar is under clinical development by Mabpharm and currently in Phase III for Chronic Urticaria Or Hives.
Pharmaceutical Technology8 小时
Broncho-Vaxom by OM Pharma for Allergic Asthma: Likelihood of Approval
Broncho-Vaxom is under clinical development by OM Pharma and currently in Phase I for Allergic Asthma. According to GlobalData, Phase I drugs for Allergic Asthma have a 78% phase transition success ...
Timeslife on MSN5 小时
From COVID to HMPV: Is History Repeating Itself in 2025?
Just when you thought 2025 was finally going to let you breathe (literally and figuratively), here comes another respiratory ...
What we know about the government's plan to cut NHS waiting lists
Wes Streeting said he doesn't want the NHS to 'go the way of Woolies' as the health secretary pledged 'a heavy emphasis on ...